BioSpace News Archive

KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Certain Patients With High-Risk, Non-Muscle Invasive Bladder Cancer

Centene Corporation announced the extension of the expiration date of the offers to exchange notes issued by WellCare Health Plans, Inc.

Mirum Pharmaceuticals, Inc. announced the pricing of its public offering of 2,400,000 shares of its common stock at a price to the public of $20.00 per share.

In the acknowledgement letter for the resubmitted NDA, the FDA stated that Nabriva’s filing was a complete, class 2 response to the complete response letter the FDA issued on April 30, 2019.

J.P. Morgan Healthcare Conference at 7:30 AM Pacific time on Wednesday, January 15, 2020.

Randomized Control Trial Results to be Presented at NANS Jan. 23-26 in Las Vegas; New, Proprietary Differential Target Multiplexed (DTM) Therapy Available on Medtronic Intellis Spinal Cord Stimulation Platform

Apellis Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 9.5 million shares of its common stock at a public offering price of $37.00 per share, for total gross proceeds of $351.5 million, before deducting underwriting discounts and commissions and expenses payable by Apellis.

Puts Spotlight on Decades of Enzo’s False Promises and Underperformance While its Board and Management Continue to Receive Excessive Compensation at Shareholders’ Expense

TraceLink Inc., a network-based platform company with the world’s largest integrated digital supply network for life sciences, today announced that Shabbir Dahod, president and CEO of TraceLink, will present at the 38th Annual J.P. Morgan Healthcare Conference for the fourth consecutive year.

Mednet, a healthcare technology company, announced a new software release of its all-in-one e-clinical solution, iMednet.